Though our approach specifically targets the LDLR dysfunction in FH, a strategy using episomes with genomic control of transgenes can be tailored to other biological conditions or clinical deficiency with potential for amelioration by iPSC intervention, further enhancing its clinical potential in tissue engineering applications. The gene discussed is LDLR; the disease is familial hyperaldosteronism.